VALN — Valneva SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1836564 ·
Last close
$5.78
Market Cap
$548.08M
52W High
$12.18
52W Low
$4.75
ADV30
29,377
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 34,938,000 | 1,600,000 | -26,172,000 | -31,203,000 | 388,276,000 | 121,526,000 | 307,155,000 |
| Mar 2026 | 30,903,000 | 4,723,000 | -23,696,000 | -32,073,000 | 372,013,000 | 105,265,000 | 295,314,000 |
| Dec 2025 | 47,687,000 | 11,616,000 | -27,685,000 | -50,019,000 | 398,836,000 | 109,650,000 | 292,668,000 |
| Sep 2025 | 29,409,000 | 5,503,000 | -37,347,000 | -44,355,000 | 448,229,000 | 143,462,000 | 297,752,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,062,000
Investing CF
$-473,000
Financing CF
$269,000
CapEx
$-3,260,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.48
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-711,194,000
Inventory
$50,584,000
Receivables
$10,132,000
ST Investments
—
EBIT TTM
$-96,599,000
Pretax Income TTM
$-137,610,000
Interest Exp TTM
$41,011,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$142,938,000
EBITDA
$-98,721,000
Free Cash Flow
$-42,501,124
Enterprise Value
$720,229,248
Total Cash
$121,526,000
Total Debt
$210,231,008
Shares Out
94,823,458
Trailing EPS
$-2.09
Book Value
$0.99
ROE
-117.8%
ROA
-16.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 174,658,000 | -81,631,000 | -115,192,000 | 398,836,000 | 292,668,000 | 106,168,000 | -52,894,000 |
| Dec 2024 | 169,578,000 | -77,769,000 | -12,247,000 | 500,032,000 | 318,779,000 | 181,253,000 | -67,218,000 |
| Dec 2023 | 153,712,000 | -82,112,000 | -101,429,000 | 460,062,000 | 331,815,000 | 128,247,000 | -202,744,000 |
| Dec 2022 | 361,303,000 | -113,443,000 | -143,279,000 | 621,344,000 | 401,547,000 | 219,797,000 | -245,343,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $532.73M | $8.07 | — |
| ETRA | Electra Therapeutics, Inc. | $567.41M | $9.04 | — |
| ALLO | Allogene Therapeutics, Inc. | $504.42M | $1.46 | — |
| DBVT | DBV Technologies S.A. | $615.92M | $9.80 | — |
| AUTL | Autolus Therapeutics plc | $481.75M | $1.81 | — |
News headlines (Yahoo Finance, 1h cache)
Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine
2026-10-08 10:09 · Yahoo
VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback
2026-10-07 21:09 · Yahoo
Valneva ADRs fall as UK revokes IXCHIQ marketing authorization
2026-10-07 20:39 · Yahoo
Valneva Provides Update on IXCHIQ® in the United Kingdom
2026-10-07 20:00 · Yahoo
Declaration of shares and voting rights - Status as of September 30, 2026
2026-10-05 16:00 · Yahoo
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
2026-09-07 11:02 · Yahoo
Declaration of shares and voting rights - Status as of August 31, 2026
2026-09-04 16:00 · Yahoo
Valneva (VALN) Q2 2026 Earnings Call Transcript
2026-08-20 19:44 · Yahoo
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
2026-08-14 05:00 · Yahoo
Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ...
2026-08-13 23:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.